Overview and Scope
Myocardial infarction is a potentially fatal disorder that develops when the heart muscle’s blood supply is suddenly interrupted, resulting in tissue damage. Myocardial infarction is triggered by high levels of low-density lipoprotein in the blood, high blood pressure, and smoking.
Sizing and Forecast
The myocardial infarction market size has grown strongly in recent years. It will grow from $1.9 billion in 2023 to $2.04 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to introduction of beta-blockers, establishment of chest pain centers, thrombolytic therapies, enomic and personalized medicine approaches, wearable cardiovascular devices.
The myocardial infarction market size is expected to see strong growth in the next few years. It will grow to $2.68 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to global health initiatives for cardiovascular health, expanded access to reperfusion therapies, rna therapeutics for cardiovascular diseases, patient-centered care models, focus on microvascular dysfunction, bioelectronic medicine. Major trends in the forecast period include advancements in cardiovascular imaging, advancements in cardiac surgery techniques, advancements in telemedicine, integration of artificial intelligence in diagnosis, innovation of digital biomarkers for risk prediction, blockchain for healthcare data security, ai-driven drug discovery, innovations in cardiac rehabilitation technologies.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/myocardial-infarction-global-market-report
Segmentation & Regional Insights
The myocardial infarction market covered in this report is segmented –
1) By Drug Class: Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors, Antithrombotic Agents, Beta-adrenergic Blockers, Vasodilators, Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin-receptor Blockers, Analgesics, Thrombolytics
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
North America was the largest region in the myocardial infarction market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial infarction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12164&type=smp
Major Driver Impacting Market Growth
An increasing number of smokers is expected to propel the growth of the myocardial infarction market going forward. A smoker is anyone who smokes cigarettes, cigars, or a pipe. Cigarette smoke contains chemicals that cause the blood to thicken and clot in veins and arteries, and a blockage brought on by a clot can result in myocardial infarction. For instance, in September 2023, according to the Office for National Statistics, a UK-based government department, the segment of the UK population aged 25 to 34 years maintained the highest percentage of current smokers, accounting for 16.3% or approximately 1.4 million individuals in 2022. This represents an increase from the previous year, when the same age group had a smoking prevalence of 15.8%, encompassing around 1.3 million people. Therefore, an increasing number of smokers is driving the growth of the myocardial infarction market.
Key Industry Players
Major companies operating in the myocardial infarction market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Boehringer Ingelheim GmbH, Merck KGaA, Daiichi Sankyo Co. Ltd., Bio-Rad Laboratories Inc., Apotex Inc., Siemens Healthcare Diagnostics Limited, Annexin Pharmaceuticals AB, Dynavax Technologies Corp, Heartseed Inc., Par Pharmaceutical Companies Inc., Tenaya Therapeutics Inc., Idorsia Pharmaceuticals Ltd., Acesion Pharma ApS, Applied Therapeutics Inc., Athersys Inc., Cardurion Pharmaceuticals Inc., Verve Therapeutics Inc., Serca Pharmaceuticals AS
The myocardial infarction market report table of contents includes:
1. Executive Summary
.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Market Size - The retail digital transformation market size has grown exponentially in recent years. It…
Market Size - The quantum computing and technologies market size has grown exponentially in recent…
Market Size - The pan-tilt-zoom (PTZ) camera market size has grown rapidly in recent years. It…
The anti-spam software global market report 2024 from The Business Research Company provides comprehensive market…
The exercise and weight loss apps global market report 2024from The Business Research Company provides…
Market Size - The medical isotopes market size has grown strongly in recent years. It will…